Developing vaccines and antibody treatments for emerging viruses
Core C: Structure, Computational, Protein Engineering
This study is working on new ways to create vaccines and treatments for diseases caused by certain viruses, aiming to help people stay healthier and better protected as these viruses change over time.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-10862999 on NIH RePORTER |
What this research studies
This research focuses on creating advanced technologies for designing vaccines and antibody therapies targeting flaviviruses and alphaviruses, which are known to cause significant human diseases. By utilizing structural biology, biophysics, and computational biology, the team will analyze the molecular structures of virus components and their interactions with antibodies. This approach aims to enhance the effectiveness of immune responses against these viruses, especially as new variants emerge. Patients may benefit from improved treatments and preventive measures against these viral infections.
Who could benefit from this research
Good fit: Ideal candidates for participation or benefit include individuals at risk of infection from flaviviruses and alphaviruses, such as those living in endemic regions.
Not a fit: Patients who are not at risk of exposure to these specific viruses may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective vaccines and antibody therapies for patients at risk of severe viral infections.
How similar studies have performed: Previous research has shown promise in developing vaccines and therapies for similar viral infections, indicating a potential for success with this approach.
Where this research is happening
Saint Louis, United States
- Washington University — Saint Louis, United States (Active)
Researchers
- Principal investigator: Kuhn, Richard J. — Washington University
- Study coordinator: Kuhn, Richard J.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.